Anaesthesia for Duchenne Muscular Dystrophy patients
Phase 4
Completed
- Conditions
- Health Condition 1: null- DUCHENNE MUSCULAR DYSTROPHY PATIENTS ASA 1 AND 2Health Condition 2: G132- Systemic atrophy primarily affecting the central nervous system in myxedema
- Registration Number
- CTRI/2017/08/009462
- Lead Sponsor
- TMMC AND LTMGH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 54
Inclusion Criteria
Patients of DMD undergoing procedural sedation techniques
Age more than 5years
Exclusion Criteria
1) unwilling for consent
2) patient not requiring any sort of sedation
3) patient needing general anaesthesia and assisted ventilation with or without tracheal intubation due to any reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dexmedetomidine and ketamine together will have a better heamodynamic profile, sedation score,as compared to given aloneTimepoint: Every 5 minutes heamodynamic profile, sedation score were checked till the completion of procedure
- Secondary Outcome Measures
Name Time Method Adverse effects of dexmedetomidine and ketamineTimepoint: At 5 minutes interval during the procedure we should study the effects of dexmedetomidine and ketamine